Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of BRAF-mutant advanced melanoma [0.03%]
纳武单抗+瑞拉利姆布与BRAF和MEK抑制剂联合治疗用于BRAF突变型晚期黑色素瘤一线治疗的每例患者花费比较
Kirollos S Hanna,Jennell Palaia,Divya Patel et al.
Kirollos S Hanna et al.
Background: The National Comprehensive Cancer Network guidelines list combination immunotherapy as the preferred first-line (1L) treatment for unresectable or metastatic melanoma over BRAF and MEK inhibitor (BRAFi/MEKi) t...
Associations between chronic active lesions and clinical outcomes in multiple sclerosis: A systematic literature review [0.03%]
多发性硬化慢性活跃病灶与临床结局之间关联的系统文献综述
Francesca Bagnato,Margaret Mordin,Nupur Greene et al.
Francesca Bagnato et al.
Background: Multiple sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative disease. Emerging evidence suggests that chronic disease processes within the central nervous system are important drivers of the on...
The financial value of improving patient access to COVID-19 antiviral therapy in Medicare Part D: A simulation study [0.03%]
改善医疗保险D部分新冠肺炎抗病毒治疗患者获取能力的经济价值：模拟研究
Andrew S Aguilar,Tyler Engel,Wesley Furnback et al.
Andrew S Aguilar et al.
Background: Nirmatrelvir-ritonavir is an approved treatment for mild to moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. Age is the leading risk fact...
The influence of medication adherence on Medicare Star Ratings: A decade-long analysis of health plan performance [0.03%]
服药依从性对医疗保险星级评价的影响：一项为期十年的健康计划绩效分析
Eric P Borrelli,Peter Saad,Nathan Barnes et al.
Eric P Borrelli et al.
Background: The Medicare Star Ratings Program, managed by the Centers for Medicare & Medicaid Services, assesses Medicare health plan performance. This program consists of quality measures that evaluate plan performance f...
Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States [0.03%]
Tirzepatide与Semaglutide和Liraglutide治疗非糖尿病肥胖或超重患者的短期成本效益分析（美国）
Ligang Liu,Jiayu Cui,Marjorie V Neidecker et al.
Ligang Liu et al.
Background: Glucagon-like peptide-1 receptor agonists and their analogues have emerged as effective pharmacotherapies for obesity. Objective: ...
Trends in first-line glucose-lowering medication use among US adults with type 2 diabetes from 2019 to 2023 [0.03%]
2019至2023年美国2型糖尿病成人患者一线降糖药物使用趋势
Duy Do,Tiffany Lee,Samuel Peasah et al.
Duy Do et al.
Background: The introduction of newer classes of glucose-lowering therapies has dramatically altered the diabetes therapeutic landscape. However, little is known about trends in the use of first-line glucose-lowering ther...
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues [0.03%]
儿科罕见病疗法研发管线带来希望并存缺口：获批、患者治疗和标价收入十年预测
Colin M Young,Sharon E Phares,Annie Kennedy et al.
Colin M Young et al.
Background: More than 10,000 rare diseases affect more than 30 million Americans, nearly 70% of which manifest in childhood. The drug development pipeline boasts hundreds of candidates for pediatric-onset rare disease, bu...
Changes in blood pressure, medication adherence, and cardiovascular-related health care use associated with the 2018 angiotensin receptor blocker recalls and drug shortages among patients with hypertension [0.03%]
血管紧张素II受体拮抗剂召回与药物短缺对高血压患者血压、用药依从性及相关医疗利用率的影响
Katherine Callaway Kim,Eric T Roberts,Julie M Donohue et al.
Katherine Callaway Kim et al.
Background: One of the largest-ever retail drug shortages began in 2018 when several angiotensin II receptor blockers (ARBs) for treating hypertension, heart failure, and chronic kidney disease-valsartan, losartan, and ir...
Health care costs and resource utilization among patients with myasthenia gravis in the United States [0.03%]
美国重症肌无力患者的医疗费用和资源利用情况
Sun A Choi,Daniel R Touchette,Kibum Kim
Sun A Choi
Background: Myasthenia gravis (MG) is a rare neuromuscular disorder with an estimated prevalence of 37 per 100,000 individuals in the United States. Despite patients with MG using a wide range of health care services, the...
Brand-to-brand nonmedical switching among interleukin-17 inhibitors or other biologics: Implications of a formulary change [0.03%]
白介素-17抑制剂或其他生物制剂的品牌转换：药单变更的影响
A Mark Fendrick,Manish Mittal,Yi Peng et al.
A Mark Fendrick et al.
Background: In 2021, a large pharmacy benefit management organization (PBM) changed preferred agents on its national formulary from one branded interleukin (IL)-17 inhibitor (TxA) to another (TxB), prompting a nonmedical ...